{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,22]],"date-time":"2026-01-22T22:45:27Z","timestamp":1769121927413,"version":"3.49.0"},"reference-count":32,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2020,5,13]],"date-time":"2020-05-13T00:00:00Z","timestamp":1589328000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2020,5,13]],"date-time":"2020-05-13T00:00:00Z","timestamp":1589328000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cardiovasc Diabetol"],"published-print":{"date-parts":[[2020,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>The recent results of Cardiovascular Outcomes Trials (CVOTs) in type 2 diabetes have clearly established the cardiovascular (CV) safety or even the benefit of two therapeutic classes, Glucagon-Like Peptide-1 receptor agonists (GLP-1 RA) and Sodium-Glucose Co-Transporter-2 inhibitors (SGLT-2i). Publication of the latest CVOTs for these therapeutic classes also led to an update of ESC guidelines and ADA\/EASD consensus report in 2019, which considers using GLP-1 RA or SGLT-2i with proven cardiovascular benefit early in the management of type 2 diabetic patient with established cardiovascular disease (CVD) or at high risk of atherosclerotic CVD. The main beneficial results of these time-to event studies are supported by conventional statistical measures attesting the effectiveness of GLP-1 RA or SGLT2i on cardiovascular events (absolute risk, absolute risk difference, relative risk, relative risk reduction, odds ratio, hazard ratio). In addition, another measure whose clinical meaning appears to be easier, the Number Needed to Treat (NNT), is often mentioned while discussing the results of CVOTs, in order to estimating the clinical utility of each drug or sometimes trying to establish a power ranking. While the value of the measure is admittedly of interest, the subtleties of its computation in time-to-event studies are little known. We provide in this article a clear and practical explanation on NNT computation methods that should be used in order to estimate its value, according to the type of study design and variables available to describe the event of interest, in any randomized controlled trial. More specifically, a focus is made on time-to-event studies of which CVOTs are part, first to describe in detail an appropriate and adjusted method of NNT computation and second to help properly interpreting NNTs with the example of CVOTs conducted with GLP-1 RA and SGLT-2i. We particularly discuss the risk of misunderstanding of NNT values in CVOTs when some specific parameters inherent in each study are not taken into account, and the following risk of erroneous comparison between NNTs across studies. The present paper highlights the importance of understanding rightfully NNTs from CVOTs and their clinical impact to get the full picture of a drug\u2019s effectiveness.<\/jats:p>","DOI":"10.1186\/s12933-020-01034-3","type":"journal-article","created":{"date-parts":[[2020,5,13]],"date-time":"2020-05-13T16:06:31Z","timestamp":1589385991000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":19,"title":["Computing and interpreting the Number Needed to Treat for Cardiovascular Outcomes Trials"],"prefix":"10.1186","volume":"19","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2838-9754","authenticated-orcid":false,"given":"Lisa","family":"Ludwig","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Patrice","family":"Darmon","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bruno","family":"Guerci","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2020,5,13]]},"reference":[{"key":"1034_CR1","doi-asserted-by":"publisher","first-page":"776","DOI":"10.1016\/S2213-8587(19)30249-9","volume":"7","author":"SL Kristensen","year":"2019","unstructured":"Kristensen SL, R\u00f8rth R, Jhund PS, Docherty KF, Sattar N, Preiss D, et al. Cardiovascular, mortality, and kidney outcomes with GLP-1 receptor agonists in patients with type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials. Lancet Diabetes Endocrinol. 2019;7:776\u201385.","journal-title":"Lancet Diabetes Endocrinol."},{"key":"1034_CR2","doi-asserted-by":"publisher","first-page":"2022","DOI":"10.1161\/CIRCULATIONAHA.118.038868","volume":"139","author":"TA Zelniker","year":"2019","unstructured":"Zelniker TA, Wiviott SD, Raz I, Im K, Goodrich EL, Furtado RHM, et al. Comparison of the effects of glucagon-like peptide receptor agonists and sodium-glucose Cotransporter 2 inhibitors for prevention of major adverse cardiovascular and renal otcomes in type 2 diabetes mellitus. Circulation. 2019;139:2022\u201331.","journal-title":"Circulation"},{"issue":"41","key":"1034_CR3","doi-asserted-by":"publisher","first-page":"2669","DOI":"10.2337\/dci18-0033","volume":"2018","author":"MJ Davies","year":"2018","unstructured":"Davies MJ, D\u2019Alessio DA, Fradkin J, Kernan WN, Mathieu C, Mingrone G, et al. Management of hyperglycemia in type 2 diabetes, 2018. A Consensus Report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care. 2018;2018(41):2669\u2013701.","journal-title":"Diabetes Care"},{"issue":"43","key":"1034_CR4","doi-asserted-by":"publisher","first-page":"487","DOI":"10.2337\/dci19-0066","volume":"2020","author":"JB Buse","year":"2020","unstructured":"Buse JB, Wexler DJ, Tsapas A, Rossing P, Mingrone G, Mathieu C, et al. 2019 Update to: management of hyperglycemia in type 2 diabetes, 2018. A Consensus Report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care. 2020;2020(43):487\u201393.","journal-title":"Diabetes Care"},{"key":"1034_CR5","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1093\/eurheartj\/ehz486","volume":"41","author":"F Cosentino","year":"2020","unstructured":"Cosentino F, Grant PJ, Aboyans V, Bailey CJ, Ceriello A, Delgado V, et al. 2019 ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD. Eur Heart J. 2020;41:255\u2013323.","journal-title":"Eur Heart J"},{"key":"1034_CR6","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1186\/1471-2288-9-21","volume":"9","author":"M Hildebrandt","year":"2009","unstructured":"Hildebrandt M, Verv\u00f6lgyi E, Bender R. Calculation of NNTs in RCTs with time-to-event outcomes: a literature review. BMC Med Res Methodol. 2009;9:21.","journal-title":"BMC Med Res Methodol"},{"key":"1034_CR7","doi-asserted-by":"publisher","first-page":"e0033","DOI":"10.5041\/RMMJ.10218","volume":"6","author":"S Suissa","year":"2015","unstructured":"Suissa S. The Number Needed to Treat: 25 years of trials and tribulations in clinical research. Rambam Maimonides Med J. 2015;6:e0033.","journal-title":"Rambam Maimonides Med J."},{"key":"1034_CR8","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1186\/s12933-019-0875-4","volume":"18","author":"S Seidu","year":"2019","unstructured":"Seidu S, Kunutsor SK, Sesso HD, Gaziano JM, Buring JE, Roncaglioni MC, et al. Aspirin has potential benefits for primary prevention of cardiovascular outcomes in diabetes: updated literature-based and individual participant data meta-analyses of randomized controlled trials. Cardiovasc Diabetol. 2019;18:70.","journal-title":"Cardiovasc Diabetol."},{"key":"1034_CR9","doi-asserted-by":"publisher","first-page":"14","DOI":"10.3389\/fcvm.2019.00014","volume":"6","author":"ND Wong","year":"2019","unstructured":"Wong ND, Shapiro MD. Interpreting the findings from the recent PCSK9 monoclonal antibody cardiovascular outcomes trials. Front Cardiovasc Med. 2019;6:14.","journal-title":"Front Cardiovasc Med."},{"key":"1034_CR10","first-page":"1226","volume":"3","author":"PK Srivastava","year":"2018","unstructured":"Srivastava PK, Claggett BL, Solomon SD, McMurray JJV, Packer M, Zile MR, et al. Estimated 5-year Number Needed to Treat to prevent cardiovascular death or heart failure hospitalization with angiotensin receptor-neprilysin inhibition vs standard therapy for patients with heart failure with reduced ejection fraction: an analysis of data from the PARADIGM-HF Trial. JAMA. 2018;3:1226\u201331.","journal-title":"JAMA"},{"key":"1034_CR11","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1186\/s12933-018-0800-2","volume":"17","author":"AC Sposito","year":"2018","unstructured":"Sposito AC, Berwanger O, de Carvalho LSF, Saraiva JFK. GLP-1RAs in type 2 diabetes: mechanisms that underlie cardiovascular effects and overview of cardiovascular outcome data. Cardiovasc Diabetol. 2018;17:157.","journal-title":"Cardiovasc Diabetol."},{"key":"1034_CR12","doi-asserted-by":"publisher","first-page":"1728","DOI":"10.1056\/NEJM198806303182605","volume":"318","author":"A Laupacis","year":"1988","unstructured":"Laupacis A, Sackett DL, Roberts RS. An assessment of clinically useful measures of the consequences of treatment. N Engl J Med. 1988;318:1728\u201333.","journal-title":"N Engl J Med"},{"key":"1034_CR13","doi-asserted-by":"publisher","first-page":"452","DOI":"10.1136\/bmj.310.6977.452","volume":"310","author":"RJ Cook","year":"1995","unstructured":"Cook RJ, Sackett DL. The Number Needed to Treat: a clinically useful measure of treatment effect. BMJ. 1995;310:452\u20134.","journal-title":"BMJ"},{"key":"1034_CR14","doi-asserted-by":"publisher","first-page":"1309","DOI":"10.1136\/bmj.317.7168.1309","volume":"317","author":"DG Altman","year":"1998","unstructured":"Altman DG. Confidence intervals for the number needed to treat. BMJ. 1998;317:1309\u201312.","journal-title":"BMJ"},{"key":"1034_CR15","doi-asserted-by":"publisher","first-page":"186","DOI":"10.1016\/S2213-8587(17)30438-2","volume":"6","author":"M Edmonds","year":"2018","unstructured":"Edmonds M, L\u00e1zaro-Mart\u00ednez JL, Alfayate-Garc\u00eda JM, Martini J, Petit J-M, Rayman G, et al. Sucrose octasulfate dressing versus control dressing in patients with neuroischaemic diabetic foot ulcers (Explorer): an international, multicentre, double-blind, randomised, controlled trial. Lancet Diabetes Endocrinol. 2018;6:186\u201396.","journal-title":"Lancet Diabetes Endocrinol."},{"key":"1034_CR16","doi-asserted-by":"publisher","first-page":"1492","DOI":"10.1136\/bmj.319.7223.1492","volume":"319","author":"DG Altman","year":"1999","unstructured":"Altman DG, Andersen PK. Calculating the Number Needed to Treat for trials where the outcome is time to an event. BMJ. 1999;319:1492\u20135.","journal-title":"BMJ"},{"key":"1034_CR17","doi-asserted-by":"publisher","first-page":"875","DOI":"10.1681\/ASN.2014020188","volume":"25","author":"SK Bowry","year":"2014","unstructured":"Bowry SK, Schoder V, Apel C. An inadvertent but explicable error in calculating Number Needed to Treat for reporting survival data. J Am Soc Nephrol. 2014;25:875\u20136.","journal-title":"J Am Soc Nephrol"},{"key":"1034_CR18","doi-asserted-by":"publisher","first-page":"2117","DOI":"10.1056\/NEJMoa1504720","volume":"373","author":"B Zinman","year":"2015","unstructured":"Zinman B, Wanner C, Lachin JM, Fitchett D, Bluhmki E, Hantel S, et al. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med. 2015;373:2117\u201328.","journal-title":"N Engl J Med"},{"key":"1034_CR19","doi-asserted-by":"publisher","first-page":"1228","DOI":"10.1056\/NEJMoa1612917","volume":"377","author":"RR Holman","year":"2017","unstructured":"Holman RR, Bethel MA, Mentz RJ, Thompson VP, Lokhnygina Y, Buse JB, et al. Effects of once-weekly exenatide on cardiovascular outcomes in type 2 diabetes. N Engl J Med. 2017;377:1228\u201339.","journal-title":"N Engl J Med"},{"key":"1034_CR20","doi-asserted-by":"publisher","first-page":"e1","DOI":"10.1016\/j.jclinepi.2010.03.004","volume":"63","author":"D Moher","year":"2010","unstructured":"Moher D, Hopewell S, Schulz KF, Montori V, G\u00f8tzsche PC, Devereaux PJ, et al. CONSORT 2010 explanation and elaboration: updated guidelines for reporting parallel group randomised trials. J Clin Epidemiol. 2010;63:e1\u201337.","journal-title":"J Clin Epidemiol"},{"key":"1034_CR21","doi-asserted-by":"publisher","first-page":"549","DOI":"10.1503\/cmaj.080484","volume":"179","author":"FA McAlister","year":"2008","unstructured":"McAlister FA. The\u2009\u00ab\u2009number needed to treat\u2009\u00bb\u2009turns 20\u2013and continues to be used and misused. Can Med Assoc J. 2008;179:549\u201353.","journal-title":"Can Med Assoc J"},{"key":"1034_CR22","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1056\/NEJMoa1603827","volume":"375","author":"SP Marso","year":"2016","unstructured":"Marso SP, Daniels GH, Brown-Frandsen K, Kristensen P, Mann JFE, Nauck MA, et al. Liraglutide and cardiovascular outcomes in type 2 diabetes. N Engl J Med. 2016;375:311\u201322.","journal-title":"N Engl J Med"},{"key":"1034_CR23","doi-asserted-by":"publisher","first-page":"1834","DOI":"10.1056\/NEJMoa1607141","volume":"375","author":"SP Marso","year":"2016","unstructured":"Marso SP, Bain SC, Consoli A, Eliaschewitz FG, J\u00f3dar E, Leiter LA, et al. Semaglutide and cardiovascular outcomes in patients with type 2 diabetes. N Engl J Med. 2016;375:1834\u201344.","journal-title":"N Engl J Med"},{"key":"1034_CR24","doi-asserted-by":"publisher","first-page":"1519","DOI":"10.1016\/S0140-6736(18)32261-X","volume":"392","author":"AF Hernandez","year":"2018","unstructured":"Hernandez AF, Green JB, Janmohamed S, D\u2019Agostino RB, Granger CB, Jones NP, et al. Albiglutide and cardiovascular outcomes in patients with type 2 diabetes and cardiovascular disease (Harmony Outcomes): a double-blind, randomised placebo-controlled trial. Lancet. 2018;392:1519\u201329.","journal-title":"Lancet"},{"key":"1034_CR25","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1016\/S0140-6736(19)31149-3","volume":"394","author":"HC Gerstein","year":"2019","unstructured":"Gerstein HC, Colhoun HM, Dagenais GR, Diaz R, Lakshmanan M, Pais P, et al. Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial. Lancet. 2019;394:121\u201330.","journal-title":"Lancet"},{"key":"1034_CR26","doi-asserted-by":"publisher","first-page":"2247","DOI":"10.1056\/NEJMoa1509225","volume":"373","author":"MA Pfeffer","year":"2015","unstructured":"Pfeffer MA, Claggett B, Diaz R, Dickstein K, Gerstein HC, K\u00f8ber LV, et al. Lixisenatide in patients with type 2 diabetes and acute coronary syndrome. N Engl J Med. 2015;373:2247\u201357.","journal-title":"N Engl J Med"},{"key":"1034_CR27","doi-asserted-by":"publisher","first-page":"841","DOI":"10.1056\/NEJMoa1901118","volume":"38","author":"M Husain","year":"2019","unstructured":"Husain M, Birkenfeld AL, Donsmark M, Dungan K, Eliaschewitz FG, Franco DR, et al. Oral semaglutide and cardiovascular outcomes in patients with type 2 diabetes. N Engl J Med. 2019;38:841\u201351.","journal-title":"N Engl J Med"},{"key":"1034_CR28","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1056\/NEJMoa1812389","volume":"380","author":"SD Wiviott","year":"2019","unstructured":"Wiviott SD, Raz I, Bonaca MP, Mosenzon O, Kato ET, Cahn A, et al. Dapagliflozin and cardiovascular outcomes in type 2 diabetes. N Engl J Med. 2019;380:347\u201357.","journal-title":"N Engl J Med"},{"key":"1034_CR29","doi-asserted-by":"publisher","first-page":"644","DOI":"10.1056\/NEJMoa1611925","volume":"377","author":"B Neal","year":"2017","unstructured":"Neal B, Perkovic V, Mahaffey KW, de Zeeuw D, Fulcher G, Erondu N, et al. Canagliflozin and cardiovascular and renal events in type 2 diabetes. N Engl J Med. 2017;377:644\u201357.","journal-title":"N Engl J Med"},{"key":"1034_CR30","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1111\/dom.13028","volume":"20","author":"HC Gerstein","year":"2018","unstructured":"Gerstein HC, Colhoun HM, Dagenais GR, Diaz R, Lakshmanan M, Pais P, et al. Design and baseline characteristics of participants in the researching cardiovascular events with a weekly INcretin in Diabetes (REWIND) trial on the cardiovascular effects of dulaglutide. Diabetes Obes Metab. 2018;20:42\u20139.","journal-title":"Diabetes Obes Metab"},{"key":"1034_CR31","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1002\/sim.5922","volume":"33","author":"NA Gouskova","year":"2014","unstructured":"Gouskova NA, Kundu S, Imrey PB, Fine JP. Number Needed to Treat for time-to-event data with competing risks. Stat Med. 2014;33:181\u201392.","journal-title":"Stat Med"},{"key":"1034_CR32","doi-asserted-by":"publisher","first-page":"1127","DOI":"10.1080\/13696998.2016.1203329","volume":"19","author":"LH Chuang","year":"2016","unstructured":"Chuang LH, Verheggen BG, Charokopou M, Gibson D, Grandy S, Kartman B. Cost-effectiveness analysis of exenatide once-weekly versus dulaglutide, liraglutide, and lixisenatide for the treatment of type 2 diabetes mellitus: an analysis from the UK NHS perspective. J Med Econ. 2016;19:1127\u201334.","journal-title":"J Med Econ."}],"container-title":["Cardiovascular Diabetology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12933-020-01034-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12933-020-01034-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12933-020-01034-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,5,12]],"date-time":"2021-05-12T23:20:32Z","timestamp":1620861632000},"score":1,"resource":{"primary":{"URL":"https:\/\/cardiab.biomedcentral.com\/articles\/10.1186\/s12933-020-01034-3"}},"subtitle":["Perspective on GLP-1 RA and SGLT-2i therapies"],"short-title":[],"issued":{"date-parts":[[2020,5,13]]},"references-count":32,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2020,12]]}},"alternative-id":["1034"],"URL":"https:\/\/doi.org\/10.1186\/s12933-020-01034-3","relation":{},"ISSN":["1475-2840"],"issn-type":[{"value":"1475-2840","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,5,13]]},"assertion":[{"value":"5 April 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 May 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 May 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Not applicable.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"Dr. LUDWIG reports personal fees from ELI LILLY and Company, outside the submitted work; Dr. DARMON reports personal fees from Eli Lilly, personal fees from Novo Nordisk, personal fees from Sanofi, personal fees from Astra Zeneca, personal fees from Merck Sharpe & Dohme, personal fees from Boehringer Ingelheim, personal fees from MundiPharma, personal fees from Novartis, personal fees from Abbott, outside the submitted work; Dr. GUERCI reports grants, personal fees and non-financial support from Sanofi, personal fees from Orkyn (provider), grants, personal fees and non-financial support from Vitalaire\/air liquide (provider), personal fees and non-financial support from Abbott, personal fees and non-financial support from Novo Nordisk, grants, personal fees and non-financial support from Eli Lilly, personal fees and non-financial support from Boehringer Ingelheim, personal fees and non-financial support from roche diagnostic, personal fees and non-financial support from Astra Zeneca, personal fees and non-financial support from MSD, grants and personal fees from medtronic, personal fees and non-financial support from dinno sant\u00e9 (provider), outside the submitted work.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"65"}}